Hal Barron, GSK
Win or lose on the marketing OK, the FDA just gunned down GSK’s bright hopes for their BCMA therapy
The FDA’s ODAC — the Oncologic Drugs Advisory Committee — has a well-known bias in favor of adding new cancer drugs to the market, even if efficacy …
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.
